Literature DB >> 27485174

Incidence, risk factors and outcomes of acute kidney injury (AKI) in patients with acute-on-chronic liver failure (ACLF) of underlying cirrhosis.

Hong Zang1, Fangfang Liu2, Hongling Liu1, Shaoli You2, Bing Zhu2, Zhihong Wan3, Shaojie Xin4.   

Abstract

BACKGROUND AND AIMS: Acute kidney injury (AKI) is a life-threatening complication in patients with acute-on-chronic liver failure (ACLF) of underlying cirrhosis. However, the characteristics of AKI in these patients have not been clarified. Our aim was to determine the incidence and risk factors of AKI and the association between AKI severity and 180-day transplant-free survival.
METHODS: We performed a retrospective cohort analysis of patients with ACLF of underlying cirrhosis in a single center from January 2009 through December 2014. AKI was defined by the criteria proposed by International Club of Ascites (ICA). The incidence and risk factors of AKI development and its relationship to 180-day transplant-free survival rates were evaluated.
RESULTS: Of 1032 patients with ACLF of underlying cirrhosis, 121 (11.72 %) had AKI at admission, and 319 (30.9 %) developed AKI during hospitalization. We established a logistic regression model including four independent factors with AKI development: MELD score [odds ratio (OR), 1.1; 95 % confidence interval (CI), 1.07-1.14], presence of ascites (OR, 3.80; 95 % CI, 2.13-6.78), sepsis/infection (OR, 2.25; 95 % CI, 1.66-3.03) and acute variceal bleed (OR, 1.78; 95 % CI, 1.00-3.19). The area under receiver operating characteristics of the model in internal and external validations were 0.95 and 0.85, respectively. Patients with mild-A AKI had a higher 180-day transplant-free survival rate (23.8 %) than patients with mild-B AKI (19.0 %) or marked AKI (5.9 %) (all p < 0.001). AKI patients with a peak value of sCr <1.5 mg/dl had higher 180-day transplant-free survival rates compared to those with a peak value of sCr ≧1.5 mg/dl (23.8 % vs. 14.7 %, p < 0.001).
CONCLUSIONS: We developed a clinical risk model for predicting development of AKI with great accuracy. Combining the ICA-AKI criteria and the peak value of sCr with 1.5 mg/dl provides a good prognostic method for patients with ACLF of underlying cirrhosis.

Entities:  

Keywords:  Acute kidney injury; Acute-on-chronic liver failure; Cirrhosis; Serum creatinine

Mesh:

Year:  2016        PMID: 27485174     DOI: 10.1007/s12072-016-9756-z

Source DB:  PubMed          Journal:  Hepatol Int        ISSN: 1936-0533            Impact factor:   6.047


  34 in total

Review 1.  Acute-on-chronic liver failure: pathophysiological basis of therapeutic options.

Authors:  Rajiv Jalan; Roger Williams
Journal:  Blood Purif       Date:  2002       Impact factor: 2.614

Review 2.  EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis.

Authors: 
Journal:  J Hepatol       Date:  2010-06-01       Impact factor: 25.083

3.  New consensus definition of acute kidney injury accurately predicts 30-day mortality in patients with cirrhosis and infection.

Authors:  Florence Wong; Jacqueline G O'Leary; K Rajender Reddy; Heather Patton; Patrick S Kamath; Michael B Fallon; Guadalupe Garcia-Tsao; Ram M Subramanian; Raza Malik; Benedict Maliakkal; Leroy R Thacker; Jasmohan S Bajaj
Journal:  Gastroenterology       Date:  2013-08-30       Impact factor: 22.682

4.  Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites.

Authors:  Paolo Angeli; Pere Gines; Florence Wong; Mauro Bernardi; Thomas D Boyer; Alexander Gerbes; Richard Moreau; Rajiv Jalan; Shiv K Sarin; Salvatore Piano; Kevin Moore; Samuel S Lee; Francois Durand; Francesco Salerno; Paolo Caraceni; W Ray Kim; Vicente Arroyo; Guadalupe Garcia-Tsao
Journal:  Gut       Date:  2015-01-28       Impact factor: 23.059

5.  Renal failure and bacterial infections in patients with cirrhosis: epidemiology and clinical features.

Authors:  Silvano Fasolato; Paolo Angeli; Lucia Dallagnese; Giulio Maresio; Erika Zola; Elena Mazza; Freddy Salinas; Silvio Donà; Stefano Fagiuoli; Antonietta Sticca; Giacomo Zanus; Umberto Cillo; Ilaria Frasson; Carla Destro; Angelo Gatta
Journal:  Hepatology       Date:  2007-01       Impact factor: 17.425

6.  Association of AKI with mortality and complications in hospitalized patients with cirrhosis.

Authors:  Justin M Belcher; Guadalupe Garcia-Tsao; Arun J Sanyal; Harjit Bhogal; Joseph K Lim; Naheed Ansari; Steven G Coca; Chirag R Parikh
Journal:  Hepatology       Date:  2012-12-06       Impact factor: 17.425

7.  An assessment of the RIFLE criteria for acute renal failure in hospitalized patients.

Authors:  Shigehiko Uchino; Rinaldo Bellomo; Donna Goldsmith; Samantha Bates; Claudio Ronco
Journal:  Crit Care Med       Date:  2006-07       Impact factor: 7.598

8.  Evaluation of acute kidney injury and its response to terlipressin in patients with acute-on-chronic liver failure.

Authors:  Ankur Jindal; Ajeet S Bhadoria; Rakhi Maiwall; Shiv K Sarin
Journal:  Liver Int       Date:  2015-09-18       Impact factor: 5.828

9.  The incidence and risk factors of acute kidney injury after hepatobiliary surgery: a prospective observational study.

Authors:  Eunjung Cho; Sun-Chul Kim; Myung-Gyu Kim; Sang-Kyung Jo; Won-Yong Cho; Hyoung-Kyu Kim
Journal:  BMC Nephrol       Date:  2014-10-23       Impact factor: 2.388

10.  Relationship between activation of the sympathetic nervous system and renal blood flow autoregulation in cirrhosis.

Authors:  Vanessa Stadlbauer; Vanessa P Stadlbauer; Gavin A K Wright; Murad Banaji; Ashis Mukhopadhya; Rajeshwar P Mookerjee; Rajeshwar Mookerjee; Kevin Moore; Rajiv Jalan
Journal:  Gastroenterology       Date:  2008-01       Impact factor: 22.682

View more
  8 in total

1.  Analysis of the high incidence of acute kidney injury associated with acute-on-chronic liver failure.

Authors:  Nan Chen; Xiaohong Chen; Xiaoqiang Ding; Jie Teng
Journal:  Hepatol Int       Date:  2018-04-28       Impact factor: 6.047

Review 2.  Precipitants of Acute-on-Chronic Liver Failure: An Opportunity for Preventative Measures to Improve Outcomes.

Authors:  Giuseppe Cullaro; Rajani Sharma; Jonel Trebicka; Andrés Cárdenas; Elizabeth C Verna
Journal:  Liver Transpl       Date:  2020-01-06       Impact factor: 5.799

3.  The Risk of Acute Kidney Injury in Hepatitis B Virus-Related Acute on Chronic Liver Failure with Tenofovir Treatment.

Authors:  Kai Zhang; Su Lin; Mingfang Wang; Jiaofeng Huang; Yueyong Zhu
Journal:  Biomed Res Int       Date:  2020-05-18       Impact factor: 3.411

Review 4.  Hepatorenal syndrome in acute-on-chronic liver failure with acute kidney injury: more questions requiring discussion.

Authors:  Songtao Liu; Qinghua Meng; Yuan Xu; Jianxin Zhou
Journal:  Gastroenterol Rep (Oxf)       Date:  2021-09-25

5.  Characteristics of acute kidney injury and its impact on outcome in patients with acute-on-chronic liver failure.

Authors:  Yue Huang; Junjun Cai; Fushuang Ha; Beichen Guo; Shaojie Xin; Zhongping Duan; Tao Han
Journal:  BMC Gastroenterol       Date:  2022-05-11       Impact factor: 3.067

6.  Risk factors for underlying comorbidities and complications in patients with hepatitis B virus-related acute-on-chronic liver failure.

Authors:  Wei-Zhen Weng; Jun-Feng Chen; Xiao-Hua Peng; Miao Huang; Jing Zhang; Jing Xiong; Hui-Juan Cao; Bing-Liang Lin
Journal:  Epidemiol Infect       Date:  2022-07-05       Impact factor: 4.434

7.  Development and validation of a nomogram for predicting overall survival in cirrhotic patients with acute kidney injury.

Authors:  Yi-Peng Wan; An-Jiang Wang; Wang Zhang; Hang Zhang; Gen-Hua Peng; Xuan Zhu
Journal:  World J Gastroenterol       Date:  2022-08-14       Impact factor: 5.374

8.  Infection deteriorating hepatitis B virus related acute-on-chronic liver failure: a retrospective cohort study.

Authors:  Xing-Ran Zhai; Jing-Jing Tong; Hong-Min Wang; Xiang Xu; Xiu-Ying Mu; Jing Chen; Zi-Feng Liu; Yu Wang; Hai-Bin Su; Jin-Hua Hu
Journal:  BMC Gastroenterol       Date:  2020-09-29       Impact factor: 3.067

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.